Regeneron (REGN) Reports Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma

EU regulator advises use of Regeneron antibody cocktail for COVID-19

(Reuters) - Europe's medicines regulator said on Friday an antibody drug combination developed by Regeneron Pharmaceuticals can be used to treat COVID-19 patients who do not require oxygen support and are at high risk of progressing to severe illness.

The recommendation can now be used as guidance in individual European nations on the possible use of the combination of... More

Cathie Wood's ARK Adds ~1.7M Shares of Twitter (TWTR), Sells Apple (AAPL), Alibaba (BABA)

Cathie Wood's ARK Investment funds added ~1.7 million shares of Twitter (NYSE: TWTR) on Thursday, in addition to buys in Tesla (NASDAQ: TSLA), Teledoc (NASDAQ: TDOC), CM Life Sciences (NASDAQ:... More

Regeneron (REGN) announces EMA Issues Advice on its Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients

EU member states can utilize the positive CHMP opinion when making national decisions about use of the antibody cocktail, prior to a potential future EMA market authorization

Regeneron has collaborated with Roche to develop and manufacture the antibody cocktail; Roche is responsible ex-U.S. and has already begun distribution in the EU

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the company's investigational COVID-19 antibody cocktail (casirivimab with imdevimab). The CHMP... More

Regeneron (REGN) Announces IDMC Finds Clear Efficacy for REGEN-COV in Phase 3 COVID-19 Outpatient Outcomes Trial

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced changes to the Phase 3 trial assessing investigational REGEN-COV (casirivimab with imdevimab) in non-hospitalized patients ("outpatients") with COVID-19, following recommendations from the Independent Data Monitoring Committee (IDMC). The IDMC found clear clinical efficacy on reducing the rate of hospitalization and death with both the 1,200 mg and 2,400 mg doses of REGEN-COV compared to placebo, and recommended stopping enrollment into the placebo group.

Regeneron is following the IDMC recommendation and will immediately stop enrolling patients... More